New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
06:35 EDTONCYOncolytics Biotech announces additional data from REO 018 study of Reolysin
Oncolytics Biotech announced additional data from the company's randomized, double-blinded clinical study examining Reolysin in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-na´ve head and neck cancers, or REO 018. The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin, paclitaxel and a placebo, while those on the test arm were treated with carboplatin, paclitaxel and Reolysin. Data was available for 165 patients, and was analyzed on an intent-to-treat basis.118 patients had loco-regional head and neck disease, with or without distal metastases. As previously disclosed, under these study conditions, test arm patients in this group had a progression-free survival, or PFS, benefit over control arm patients through five cycles of therapy. An intent-to-treat analysis of the 118 loco-regional patients using Type II censoring from the median PFS in each arm showed a statistically significant improvement in PFS for the test arm versus the control arm. An intent-to-treat analysis of the overall survival, or OS, of the 118 patients with loco-regional disease was performed on all patients to the median PFS in each arm, censoring any patients who received post-discontinuation therapy at the date at which they commenced the first of these therapies. This analysis demonstrated a statistically significant improvement in OS for the test arm versus the control arm. The 118 patients with loco-regional head and neck disease, with or without distal metastases, were evaluated for percentage magnitude of tumor shrinkage at the first post-treatment scan. The test arm demonstrated statistically significantly better tumor stabilization or shrinkage than the control arm.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
06:34 EDTONCYOncolytics to present survival data from lung cancer candidate reolysin
Subscribe for More Information
August 26, 2015
06:33 EDTONCYOncolytics completes enrollment in Phase II lung cancer study of Reolysin
Subscribe for More Information
06:32 EDTONCYOncolytics completes enrollment in Reolysin Phase II study
Oncolytics Biotech announced that enrollment has been completed in a randomized Phase II study of Reolysin in patients with previously treated advanced or metastatic non-small cell lung cancer, or NSCLC. The trial is being sponsored and conducted by the NCIC Clinical Trials Group, or NCIC CTG, at Queen's University in Kingston, Ontario. The primary objective of the trial is to evaluate the effect of Reolysin in combination with standard salvage chemotherapy on the progression free survival of patients with advanced or metastatic non-small cell lung cancer. The secondary objectives are to determine the tolerability and toxicity of the therapeutic combination; to investigate additional potential measures of efficacy, including progression rates at three months, objective response rate and overall survival; and to explore potential molecular factors predictive of response. Although accrual is complete, patient follow-up will continue until planned analyses have been conducted.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use